Avadel pharmaceuticals announces fda acceptance of new drug application for ft218 in adults with narcolepsy for the treatment of excessive daytime sleepiness and cataplexy

Ft218 assigned pdufa target action date of october 15, 2021 ft218 assigned pdufa target action date of october 15, 2021

AVDL Ratings Summary

AVDL Quant Ranking